202 related articles for article (PubMed ID: 20542448)
1. Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.
Cerussi AE; Tanamai VW; Mehta RS; Hsiang D; Butler J; Tromberg BJ
Acad Radiol; 2010 Aug; 17(8):1031-9. PubMed ID: 20542448
[TBL] [Abstract][Full Text] [Related]
2. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.
Cerussi AE; Tanamai VW; Hsiang D; Butler J; Mehta RS; Tromberg BJ
Philos Trans A Math Phys Eng Sci; 2011 Nov; 369(1955):4512-30. PubMed ID: 22006904
[TBL] [Abstract][Full Text] [Related]
3. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Tromberg BJ; Zhang Z; Leproux A; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue BW; Jiang S; Kaufman PA; Yodh AG; Chung SH; Schnall M; Snyder BS; Hylton N; Boas DA; Carp SA; Isakoff SJ; Mankoff D;
Cancer Res; 2016 Oct; 76(20):5933-5944. PubMed ID: 27527559
[TBL] [Abstract][Full Text] [Related]
4. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy.
O'Sullivan TD; Leproux A; Chen JH; Bahri S; Matlock A; Roblyer D; McLaren CE; Chen WP; Cerussi AE; Su MY; Tromberg BJ
Breast Cancer Res; 2013 Feb; 15(1):R14. PubMed ID: 23433249
[TBL] [Abstract][Full Text] [Related]
5. Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
Tank A; Peterson HM; Pera V; Tabassum S; Leproux A; O'Sullivan T; Jones E; Cabral H; Ko N; Mehta RS; Tromberg BJ; Roblyer D
Breast Cancer Res; 2020 Mar; 22(1):29. PubMed ID: 32169100
[TBL] [Abstract][Full Text] [Related]
6. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
7. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Bahri S; Chen JH; Mehta RS; Carpenter PM; Nie K; Kwon SY; Yu HJ; Nalcioglu O; Su MY
Ann Surg Oncol; 2009 Jun; 16(6):1619-28. PubMed ID: 19333654
[TBL] [Abstract][Full Text] [Related]
8. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.
Cochran JM; Busch DR; Leproux A; Zhang Z; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue B; Jiang S; Kaufman PA; Chung SH; Schnall M; Snyder BS; Hylton N; Carp SA; Isakoff SJ; Mankoff D; Tromberg BJ; Yodh AG
J Biomed Opt; 2018 Oct; 24(2):1-11. PubMed ID: 30338678
[TBL] [Abstract][Full Text] [Related]
9. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study.
Jakubowski DB; Cerussi AE; Bevilacqua F; Shah N; Hsiang D; Butler J; Tromberg BJ
J Biomed Opt; 2004; 9(1):230-8. PubMed ID: 14715078
[TBL] [Abstract][Full Text] [Related]
10. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy.
Tran WT; Childs C; Chin L; Slodkowska E; Sannachi L; Tadayyon H; Watkins E; Wong SL; Curpen B; El Kaffas A; Al-Mahrouki A; Sadeghi-Naini A; Czarnota GJ
Oncotarget; 2016 Apr; 7(15):19762-80. PubMed ID: 26942698
[TBL] [Abstract][Full Text] [Related]
12. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
13. Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
Ueda S; Saeki T
Breast Cancer; 2014 Nov; 21(6):776-9. PubMed ID: 24795075
[TBL] [Abstract][Full Text] [Related]
14. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
[TBL] [Abstract][Full Text] [Related]
15. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.
Cochran JM; Chung SH; Leproux A; Baker WB; Busch DR; DeMichele AM; Tchou J; Tromberg BJ; Yodh AG
Phys Med Biol; 2017 Jun; 62(12):4637-4653. PubMed ID: 28402286
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.
Cerussi A; Hsiang D; Shah N; Mehta R; Durkin A; Butler J; Tromberg BJ
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4014-9. PubMed ID: 17360469
[TBL] [Abstract][Full Text] [Related]
18. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study.
Delille JP; Slanetz PJ; Yeh ED; Halpern EF; Kopans DB; Garrido L
Radiology; 2003 Jul; 228(1):63-9. PubMed ID: 12775851
[TBL] [Abstract][Full Text] [Related]
19. Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
Böttcher J; Renz DM; Zahm DM; Pfeil A; Fallenberg EM; Streitparth F; Maurer MH; Hamm B; Engelken FJ
Acta Oncol; 2014 Jun; 53(6):759-68. PubMed ID: 24299492
[TBL] [Abstract][Full Text] [Related]
20. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.
Ueda S; Roblyer D; Cerussi A; Durkin A; Leproux A; Santoro Y; Xu S; O'Sullivan TD; Hsiang D; Mehta R; Butler J; Tromberg BJ
Cancer Res; 2012 Sep; 72(17):4318-28. PubMed ID: 22777823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
